OTLK Outlook Therapeutics, Inc. Insider Trading

Director Yezan Munther Haddadin bought 29,000 shares of OTLK at $0.83; 4 other insiders bought within 14 days; stock at $0.81, -76.1% from 52-week high.

Director Yezan Munther Haddadin purchased 29,000 shares at $0.83 on 2026-06-02, increasing his holdings to 66,167 shares, a +78.0% increase in position size. The company generated Revenue $1,505,322.00 in the latest quarter but reported Net income $-4,453,081.00 and remains unprofitable on a full-year basis, creating a contrasting backdrop of fundamental weakness. The stock has traded at $0.81 currently, down -76.1% from its 52-week high of $3.39, yet has rallied +208.6% over the past 30 days and +87.6% over 90 days. This filing documents part of a broader cluster: 4 other insiders also bought within the past 14 days, marking a multi-insider transaction pattern during a period of sharp price recovery from cycle lows. His prior buy at this ticker on 2026-05-26 achieved a +84.9% 30-day return and +84.9% 90-day return, demonstrating recent successful prior accumulation at OTLK.

Director Sukhtian acquired 8,539,709 shares of OTLK at $0.59 ($5.0M) via private placement; 4 other insiders bought in prior 14 days.

Ghiath M. Sukhtian, Director, acquired 8,539,709 shares at $0.59 on 2026-05-28 for a total of $4,999,999.62, increasing his non-derivative holding from 13,552,359 to 22,092,068 shares (+63.0%). However, this transaction is a private placement—not a discretionary open-market purchase—and therefore does not signal insider conviction driven by market conditions. The larger context includes a cluster pattern: 4 other insiders also bought within the past 14 days, and the company is operating unprofitably with net income of $-4,453,081.00 against revenue of $1,505,322.00 in the latest quarter. Sukhtian's position also includes substantial derivative holdings (15,488,570 total warrant shares across six ownership vehicles), meaning his overall economic interest extends well beyond the non-derivative shares recorded in this Form 4. The current stock price of $0.84 represents a -75.2% drawdown from the 52-week high of $3.39, though the 30-day and 90-day price movements (+220.4% and +99.2%, respectively) suggest recent volatility. The multi-insider participation and private placement structure should be tracked to understand capitalization dynamics and warrant vesting schedules.

OTLK Director Sukhtian bought 122,174 shares at $0.41; holdings surge +3593.4%; 3 other insiders bought in past 14 days

Faisal Ghiath Sukhtian purchased 122,174 shares of Outlook Therapeutics at $0.41 on 2026-05-27, expanding his holdings from 3,400 shares to 125,574 shares, a net change of +3593.4% versus pre-transaction holdings. The transaction occurred in a cluster context: 3 other insiders also purchased shares within the past 14 days, suggesting coordinated or independently motivated accumulation at low price levels. The current price of $0.52 reflects a 30-day gain of +82.5%, though the stock remains -84.7% below its 52-week high of $3.39. Against the company's financial backdrop of $1.5M quarterly revenue and $-4.5M net loss in the latest quarter, the multi-insider buying pattern during depressed valuation warrants investor attention to whether insiders see inflection potential or whether the cluster represents passive or scheduled acquisitions.

Director Yezan Munther Haddadin bought 34,000 shares of OTLK at $0.44; stock down 84.7% from 52-week high, insider's 1 prior buy yielded -39.5% 90d return.

Director Yezan Munther Haddadin purchased 34,000 shares at $0.44 on 2026-05-26, increasing his holdings from 3,167 to 37,167 shares. The purchase occurs at depressed absolute levels—the stock is currently $0.52, down 84.7% from its 52-week high of $3.39—but the transaction price of $0.44 is below current levels. Notably, his single prior buy at OTLK on 2024-03-28 resulted in a -39.5% 90-day return, indicating this insider has not demonstrated timing accuracy at this ticker. The company remains unprofitable with a quarterly revenue of $1,505,322.00 and net income of $-4,453,081.00, providing limited fundamental support for accumulation at present price levels.

Director Kurt J Hilzinger purchases 400,000 shares of OTLK at $0.44, raising stake 1691.0% to 423.7K shares

Director Kurt J Hilzinger acquired 400,000 shares at $0.44 on 2026-05-26, a massive 1691.0% increase in his position from 23.7K to 423.7K shares. The company is deeply unprofitable (net income of $-4.5M against quarterly revenue of $1.5M) and trading 84.7% below its 52-week high, yet the stock has gained 82.5% over the past 30 days. This substantial insider accumulation at a heavily depressed valuation—combined with the director's dramatic concentration of equity—occurs within a distressed fundamental context and following steep recent price recovery.